文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Development and implementation of a prognostic model for clear cell renal cell carcinoma based on heterogeneous TLR4 expression.

作者信息

Zhou Qingbo, Sun Qiang, Shen Qi, Li Xinsheng, Qian Jijiang

机构信息

Department of Internal Medicine, Shaoxing Yuecheng People's Hospital, Shaoxing, China.

Department of Medical Imaging, Shaoxing Yuecheng People's Hospital, Shaoxing, China.

出版信息

Heliyon. 2024 Feb 12;10(4):e25571. doi: 10.1016/j.heliyon.2024.e25571. eCollection 2024 Feb 29.


DOI:10.1016/j.heliyon.2024.e25571
PMID:38380017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10877190/
Abstract

OBJECTIVE: Clear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cell carcinomas and has the worst prognosis, originating from renal tubular epithelial cells. Toll-like receptor 4 (TLR4) plays a crucial role in ccRCC proliferation, infiltration, and metastasis. The aim of this study was to construct a prognostic scoring model for ccRCC based on TLR4 expression heterogeneity and to explore its association with immune infiltration, thereby providing insights for the treatment and prognostic evaluation of ccRCC. METHODS: Using R software, a differential analysis was conducted on normal samples and ccRCC samples, and in conjunction with the KEGG database, a correlation analysis for the clear cell renal cell carcinoma pathway (hsa05211) was carried out. We observed the expression heterogeneity of TLR4 in the TCGA-KIRC cohort and identified its related differential genes (TRGs). Based on the expression levels of TRGs, consensus clustering was employed to identify TLR4-related subtypes, and further clustering heatmaps, principal component, and single-sample gene set enrichment analyses were conducted. Overlapping differential genes (ODEGs) between subtypes were analysed, and combined with survival data, univariate Cox regression, LASSO, and multivariate Cox regression were used to establish a prognostic risk model for ccRCC. This model was subsequently evaluated through ROC analysis, risk factor correlation analysis, independent prognostic factor analysis, and intergroup differential analysis. The ssGSEA model was employed to explore immune heterogeneity in ccRCC, and the performance of the model in predicting patient prognosis was evaluated using box plots and the oncoPredict software package. RESULTS: In the TCGA-KIRC cohort, TLR4 expression was notably elevated in ccRCC samples compared to normal samples, correlating with improved survival in the high-expression group. The study identified distinct TLR4-related differential genes and categorized ccRCC into three subtypes with varied survival outcomes. A risk prognosis model based on overlapping differential genes was established, showing significant associations with immune cell infiltration and key immune checkpoints (PD-1, PD-L1, CTLA4). Additionally, drug sensitivity differences were observed between risk groups. CONCLUSION: In the TCGA-KIRC cohort, the expression of TLR4 in ccRCC samples exhibited significant heterogeneity. Through clustering analysis, we identified that the primary immune cells across subtypes are myeloid-derived suppressor cells, central memory CD4 T cells, and regulatory T cells. Furthermore, we successfully constructed a prognostic risk model for ccRCC composed of 17 genes. This model provides valuable references for the prognosis prediction and treatment of ccRCC patients.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/ae7326b5b6b6/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/75dd42f3402c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/4efa16f97f33/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/19c1b448ec99/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/2256207fa354/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/0d037159e8db/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/b0b6d1cfad44/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/ae7326b5b6b6/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/75dd42f3402c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/4efa16f97f33/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/19c1b448ec99/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/2256207fa354/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/0d037159e8db/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/b0b6d1cfad44/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfa/10877190/ae7326b5b6b6/gr7.jpg

相似文献

[1]
Development and implementation of a prognostic model for clear cell renal cell carcinoma based on heterogeneous TLR4 expression.

Heliyon. 2024-2-12

[2]
Bioinformatics screening of prognostic immune-related genes in renal clear cell carcinoma.

J Appl Genet. 2025-5

[3]
Comprehensive Analysis of mC RNA Methylation Regulator Genes in Clear Cell Renal Cell Carcinoma.

Int J Genomics. 2021-9-28

[4]
Prognosis and progression of phagocytic regulatory factor-related gene combinations in clear cell renal cell carcinoma (ccRCC).

Transl Cancer Res. 2024-9-30

[5]
A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma.

Front Genet. 2022-10-19

[6]
TLR4 predicts patient prognosis and immunotherapy efficacy in clear cell renal cell carcinoma.

J Cancer. 2023-7-16

[7]
A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.

Int J Mol Sci. 2023-3-10

[8]
Construction and Validation of Protein Expression-related Prognostic Models in Clear Cell Renal Cell Carcinoma.

J Cancer. 2023-3-27

[9]
NUDT1 Could Be a Prognostic Biomarker and Correlated with Immune Infiltration in Clear Cell Renal Cell Carcinoma.

Appl Bionics Biomech. 2022-12-26

[10]
Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.

Front Oncol. 2022-12-22

引用本文的文献

[1]
Integrating mitophagy-associated lncRNAs to predict prognosis and therapeutic response in clear cell renal cell carcinoma.

Int Urol Nephrol. 2025-6-27

[2]
Migrasome-related lncRNAs predict prognosis and immune response of clear cell renal cell carcinoma.

Transl Androl Urol. 2025-5-30

[3]
Shared hub genes in membranous nephropathy and kidney renal clear cell carcinoma: investigating molecular overlap and tumor progression.

Discov Oncol. 2025-6-9

[4]
Comprehensive evaluation of flumazenil adverse reactions: Insights from FAERS data and signal detection algorithms.

Medicine (Baltimore). 2025-3-7

[5]
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives.

Mol Cancer. 2024-7-16

本文引用的文献

[1]
Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas.

Nat Commun. 2023-9-13

[2]
TLR4 predicts patient prognosis and immunotherapy efficacy in clear cell renal cell carcinoma.

J Cancer. 2023-7-16

[3]
Fusobacterium nucleatum-derived small extracellular vesicles facilitate tumor growth and metastasis via TLR4 in breast cancer.

BMC Cancer. 2023-5-23

[4]
The Role of the Adapter Protein Anks1a in the Regulation of Breast Cancer Cell Motility.

Biochemistry (Mosc). 2022-12

[5]
CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.

Molecules. 2022-12-2

[6]
DHRS7 is an immune-related prognostic biomarker of KIRC and pan-cancer.

Front Genet. 2022-10-6

[7]
Analysis of genomes and transcriptomes of clear cell renal cell carcinomas identifies mutations and gene expression changes in the TGF-beta pathway.

Front Genet. 2022-9-15

[8]
SHMT2 regulates serine metabolism to promote the progression and immunosuppression of papillary renal cell carcinoma.

Front Oncol. 2022-8-30

[9]
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.

Genome Med. 2022-9-15

[10]
Advantages of organ-sparing treatment approaches in metastatic kidney cancer.

J Cancer Res Clin Oncol. 2023-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索